Polyplus Is Now Part of Sartorius
Improve Process Economics in Cell and Gene Therapies
Polyplus is a leading upstream solutions provider for advanced biologic and cell and gene therapy production from research to commercial scale.
An innovator in nucleic acid delivery, the legacy portfolio features process-centric transfection reagents, kits, and support services for viral and non-viral delivery. Custom plasmid vector design and plasmid and protein manufacturing were integrated into the offer in 2022 to expand the products and services portfolio to help the industry optimize process economics while meeting strict scientific and regulatory standards.
Explore Polyplus´ Solutions
FAQs - Transfection Reagents and Plasmids
Find more FAQs on cell & gene therapy here.
Our transfection reagents are manufactured in compliance with the ICH Q7 GMP part II guideline that ensure a validated and aseptic manufacturing process.
For lentivirus production, we recommend FectoVIR®-LV as it is currently the best product for this application, both in adherent and suspension cell culture systems.
PEIpro® and FectoVIR®-AAV are different both in terms of molecular structure and formulation. FectoVIR-AAV is especially well suited for AAV production in suspension cells.
Our unique and scalable proprietary process allows plasmid production from 50mg to 20g in Research, HQ & GMP grades.
Within the LNP formulation, our Cationic lipids can modulate physicochemical properties and impact subsequent potency and biodistribution of formulated LNPs while improving mRNA stability.
